A randomized, double-blind study of AMG 108 (a fully human monoclonal antibody to IL-1R1) in patients with osteoarthritis of the knee

Arthritis Research and Therapy

Volumn 13, Issue 4, 2011, Pages

  Cohen, Stanley B ^a   Proudman, Susanna ^b   Kivitz, Alan J ^c   Burch, Francis X ^d   Donohue, John P ^e   Burstein, Deborah ^f   Sun, Yu Nien ^g   Banfield, Christopher ^g   Vincent, Michael S ^g   Ni, Liyun ^g   Zack, Debra J ^g  

^a METROPLEX CLINICAL RESEARCH CENTER   (United States)

^b ROYAL ADELAIDE HOSPITAL   (Australia)

^c Altoona Arthritis and Osteoporosis Center   (United States)

^d San Antonio Center for Clinical Research   (United States)

^e LERNER RESEARCH INSTITUTE   (United States)

^f BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^g AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMG 108; ANTIRHEUMATIC AGENT; C REACTIVE PROTEIN; PLACEBO; UNCLASSIFIED DRUG; INTERLEUKIN 1 RECEPTOR; MONOCLONAL ANTIBODY;

ABDOMINAL PAIN; ADULT; AREA UNDER THE CURVE; ARTICLE; BLOODY DIARRHEA; CONTROLLED STUDY; DEATH; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG SYNOVIAL FLUID LEVEL; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEADACHE; HUMAN; HUMAN CELL; INJECTION SITE REACTION; KNEE OSTEOARTHRITIS; LEUKOPENIA; LOBAR PNEUMONIA; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MULTIPLE ORGAN FAILURE; NEUTROPENIA; NEUTROPHIL COUNT; PAIN ASSESSMENT; PANCREATITIS; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY FAILURE; SEPSIS; SIDE EFFECT; SUPRAVENTRICULAR TACHYCARDIA; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; TREATMENT RESPONSE; UNSTABLE ANGINA PECTORIS; UPPER RESPIRATORY TRACT INFECTION; VISUAL ANALOG SCALE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DOSE RESPONSE; DRUG ANTAGONISM; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; PAIN; SUBCUTANEOUS DRUG ADMINISTRATION;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; OSTEOARTHRITIS, KNEE; PAIN; RECEPTORS, INTERLEUKIN-1;

EID: 79960862976     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar3430     Document Type: Article

References (20)

1. Cooper C. Osteoarthritis and related disorders: epidemiology. Rheumatology 1998, 2. London: Mosby, Klippel JH, Dieppe PA, 8.2.1-8.
2. Samuels J, Krasnokutsky S, Abramson SB. Osteoarthritis: a tale of three tissues. Bull NYU Hosp Jt Dis 2008, 66:244-250.
3. LeGrand A, Fermor B, Fink C, Pisetsky DS, Weinberg JB, Vail TP, Guilak F. Interleukin-1, tumor necrosis factor alpha, and interleukin-17 synergistically up-regulate nitric oxide and prostaglandin E2 production in explants of human osteoarthritic knee menisci. Arthritis Rheum 2001, 44:2078-2083. 10.1002/1529-0131(200109)44:9<2078::AID-ART358>3.0.CO;2-J, 11592370.
4. Murakami S, Lefebvre V, de Crombrugghe B. Potent inhibition of the master chondrogenic factor Sox9 gene by interleukin-1 and tumor necrosis factor-alpha. J Biol Chem 2000, 275:3687-3692. 10.1074/jbc.275.5.3687, 10652367.
5. Petrov R, MacDonald MH, Tesch AM, Benton HP. Inhibition of adenosine kinase attenuates interleukin-1- and lipopolysaccharide-induced alterations in articular cartilage metabolism. Osteoarthritis Cartilage 2005, 13:250-257. 10.1016/j.joca.2004.12.004, 15727892.
6. Presle N, Cipolletta C, Jouzeau JY, Abid A, Netter P, Terlain B. Cartilage protection by nitric oxide synthase inhibitors after intraarticular injection of interleukin-1beta in rats. Arthritis Rheum 1999, 42:2094-2102. 10.1002/1529-0131(199910)42:10<2094::AID-ANR9>3.0.CO;2-Y, 10524680.
7. Richette P, Francois M, Vicaut E, Fitting C, Bardin T, Corvol M, Savouret JF, Rannou F. A high interleukin 1 receptor antagonist/IL-1beta ratio occurs naturally in knee osteoarthritis. J Rheumatol 2008, 35:1650-1654.
8. Vuolteenaho K, Moilanen T, Hamalainen M, Moilanen E. Regulation of nitric oxide production in osteoarthritic and rheumatoid cartilage: role of endogenous IL-1 inhibitors. Scand J Rheumatol 2003, 32:19-24. 10.1080/03009740310000355, 12635941.
9. Caron JP, Fernandes JC, Martel-Pelletier J, Tardif G, Mineau F, Geng C, Pelletier JP. Chondroprotective effect of intraarticular injections of interleukin-1 receptor antagonist in experimental osteoarthritis: suppression of collagenase-1 expression. Arthritis Rheum 1996, 39:1535-1544. 10.1002/art.1780390914, 8814066.
10. Pelletier JP, Caron JP, Evans C, Robbins PD, Georgescu HI, Jovanovic D, Fernandes JC, Martel-Pelletier J. In vivo suppression of early experimental osteoarthritis by interleukin-1 receptor antagonist using gene therapy. Arthritis Rheum 1997, 40:1012-1019. 10.1002/art.1780400604, 9182910.
11. Fernandes J, Tardif G, Martel-Pelletier J, Lascau-Coman V, Dupuis M, Moldovan F, Sheppard M, Krishnan BR, Pelletier JP. In vivo transfer of interleukin-1 receptor antagonist gene in osteoarthritic rabbit knee joints: prevention of osteoarthritis progression. Am J Pathol 1999, 154:1159-1169. 10.1016/S0002-9440(10)65368-0, 1866546, 10233854.
12. Frisbie DD, Ghivizzani SC, Robbins PD, Evans CH, McIlwraith CW. Treatment of experimental equine osteoarthritis by in vivo delivery of the equine interleukin-1 receptor antagonist gene. Gene Ther 2002, 9:12-20. 10.1038/sj.gt.3301608, 11850718.
13. Fernandes JC, Martel-Pelletier J, Pelletier JP. The role of cytokines in osteoarthritis pathophysiology. Biorheology 2002, 39:237-246.
14. Bashir A, Gray ML, Hartke J, Burstein D. Nondestructive imaging of human cartilage glycosaminoglycan concentration by MRI. Magn Reson Med 1999, 41:857-865. 10.1002/(SICI)1522-2594(199905)41:5<857::AID-MRM1>3.0.CO;2-E, 10332865.
15. Ren K, Torres R. Role of interleukin-1beta during pain and inflammation. Brain Res Rev 2009, 60:57-64. 10.1016/j.brainresrev.2008.12.020, 3076185, 19166877.
16. Chevalier X, Giraudeau B, Conrozier T, Marliere J, Kiefer P, Goupille P. Safety study of intraarticular injection of interleukin 1 receptor antagonist in patients with painful knee osteoarthritis: a multicenter study. J Rheumatol 2005, 32:1317-1323.
17. Altman R, Asch E, Bloch D, Bole G, Borenstein D, Brandt K, Christy W, Cooke TD, Greenwald R, Hochberg M, et al. Development of criteria for the classification and reporting of osteoarthritis: classification of osteoarthritis of the knee: Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthritis Rheum 1986, 29:1039-1049. 10.1002/art.1780290816, 3741515.
18. Pelletier JP, DiBattista JA, Roughley P, McCollum R, Martel-Pelletier J. Cytokines and inflammation in cartilage degradation. Rheum Dis Clin North Am 1993, 19:545-568.
19. Yang KG, Raijmakers NJ, van Arkel ER, Caron JJ, Rijk PC, Willems WJ, Zijl JA, Verbout AJ, Dhert WJ, Saris DB. Autologous interleukin-1 receptor antagonist improves function and symptoms in osteoarthritis when compared to placebo in a prospective randomized controlled trial. Osteoarthritis Cartilage 2008, 16:498-505. 10.1016/j.joca.2007.07.008, 17825587.
20. Chevalier X, Goupille P, Beaulieu AD, Burch FX, Bensen WG, Conrozier T, Loeuille D, Kivitz AJ, Silver D, Appleton BE. Intraarticular injection of anakinra in osteoarthritis of the knee: a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 2009, 61:344-352. 10.1002/art.24096, 19248129.